Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Cetuximab

palliative care group first-line regimen (FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab)+ compound kushen injection

palliative care group first-line regimen (FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab)

FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml, at least 4 cycles of chemotherapy.

palliative care group first-line scheme+compound kushen injection

FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab

palliative care group first-line scheme

jie Li

Jie Li

To clarify the effectiveness and safety of compound kushen injection in the treatment of advanced colorectal cancer.

This study include a multi-center, randomized, parallel controlled clinical trial.The randomized clinical trial will enroll approximately 318 patients. Participants will be randomly divided into experimental (n=159) and control groups (n=159).Patients in the experimental group was treated with palliative care group first-line scheme + compound kushen injection. Patients in the control group will receive palliative care group first-line scheme.The primary endpoint is PFS. The research protocol was approved by the relevant ethics committees, and the study was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. Patients gave written informed consent to participate in the trial.

Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer

Survival Benefit of Compound Kushen Injection in Treatment of Advanced Colorectal Cancer Based on Real World Registration Platform

The probability of patients surviving more than 1 year after treatment

Refers to the proportion of patients with tumor progression or death since enrollment of treatment.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer	NCT05894694	Advanced Colore...	palliative care... palliative care...	18 Years -	Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer	NCT05894694	Advanced Colore...	palliative care... palliative care...	18 Years -	Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Spots Global Cancer Trial Database for compound kushen injection